Tempest Therapeutics Reports Dire Q1 Financials: Cash Dwindles to $1.8M Amid $27.7M Net Loss
TPST sits 34% above its 52-week low of $1.5.
Summary
Tempest Therapeutics reported alarming first-quarter 2026 financial results, with cash and cash equivalents plummeting to $1.8 million from $7.7 million at the end of 2025. The company posted a substantial net loss of $27.7 million for the quarter, a significant increase from $10.9 million in the prior year, indicating a rapid cash burn. This critical cash position, especially for a micro-cap biotech that previously issued a 'going concern' warning in its 10-K, signals an urgent need for further financing. While the business update reiterated positive interim clinical data for TPST-2003, which was previously disclosed in a May 6th 8-K, the dire financial situation overshadows these developments. Investors will be closely watching for any announcements regarding capital raises or strategic financing to address the company's extremely short cash runway.
At the time of this announcement, TPST was trading at $2.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30M. The 52-week trading range was $1.50 to $12.23. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.